PERRIGO COMPANY PLC ITEM 2.02. Results of Operations and Financial Condition
On
The Company provides non-GAAP financial measures as additional information that it believes is useful to investors and analysts in evaluating the performance of the Company's ongoing operating trends, facilitating comparability between periods and companies in similar industries and assessing the Company's prospects for future performance. These non-GAAP financial measures exclude items, such as impairment charges, amortization expense, restructuring charges, and acquisition and integration-related charges, that by their nature affect comparability of operational performance or that we believe obscure underlying business operational trends. The non-GAAP measures the Company provides are consistent with how management analyzes and assesses the operating performance of the Company, and disclosing them provides investor insight into management's view of the business. Management uses these adjusted financial measures for planning and forecasting in future periods, and evaluating segment and overall operating performance. In addition, management uses certain of the profit measures as factors in determining compensation.
Non-GAAP measures related to profit measurements, which include adjusted gross profit, adjusted operating income, adjusted net income and adjusted diluted earnings per share, are useful to investors as they provide them with supplemental information to enhance their understanding of the Company's underlying business performance and trends, and enhance the ability of investors and analysts to compare the Company's period-to-period financial results. Management believes that adjusted gross margin and adjusted operating margin are useful to investors, in addition to the reasons discussed above, by allowing them to more easily compare and analyze trends in the Company's peer business group and assisting them in comparing the Company's overall performance to that of its competitors. The Company discloses adjusted net sales, which excludes operating results attributable to the infant foods product line and the animal health business in order to provide information about sales of the Company's continuing business. In addition, the Company discloses net sales growth and adjusted net sales growth on a constant currency basis to provide information about sales of the Company's continuing business excluding the exogenous impact of foreign exchange. The Company believes these supplemental financial measures provide investors with consistency in financial reporting, enabling meaningful comparisons of past, present and future underlying operating results, and also facilitate comparison of the Company's operating performance to the operating performance of its competitors.
In addition, this year we made adjustments for the impact of the ranitidine market withdrawal, which included the reversal of returns and inventory writedowns and other costs, which increased adjusted net sales and related profit measures. Product recalls occur from time-to-time in our industry and we have experienced them in the past and they may recur in the future. However, we do not view the impact of the ranitidine recall as reflective of our operating performance, in particular given the industry-wide nature of this action. Management believes that these adjustments are useful to investors and improve the comparability of operational performance between periods, and the Company continues to manufacture and sell other products that treat the same conditions as ranitidine products.
Reported results for the periods below were adjusted for the following items:
Three Months Ended
• Amortization expense related primarily to acquired intangible assets
• Change in financial assets
• (Gain) Loss on investment securities
• Acquisition and integration-related charges and contingent
consideration adjustments
• Restructuring charges and other termination benefits
• Impairment charges
• Separation and reorganization expense
• (Gain) loss on divestitures
• Unusual litigation
--------------------------------------------------------------------------------
• Foreign currency translation movement
• Ranir net sales • Non-GAAP tax adjustments
Three Months Ended
• Amortization expense related primarily to acquired intangible assets
• Change in financial assets
• Loss on investment securities
• Acquisition and integration-related charges and contingent
consideration adjustments
• Restructuring charges and other termination benefits
• Milestone income related to royalty rights
• Impairment charges
• Separation and reorganization expense
• (Gain) loss on divestitures
• Unusual litigation
• Foreign currency translation movement
• Animal health net sales • Infant foods net sales • Non-GAAP tax adjustments
Twelve Months Ended
• Amortization expense related primarily to acquired intangible assets
• Change in financial assets
• (Gain) Loss on investment securities
• Acquisition and integration-related charges and contingent
consideration adjustments
• Restructuring charges and other termination benefits
• Impairment charges
• Separation and reorganization expense
• (Gain) loss on divestitures
• Unusual litigation
• Foreign currency translation movement
• Ranir net sales • Non-GAAP tax adjustments
• Ranitidine market withdrawal
• Asset abandonment
• Operating results attributable to held-for-sale business
• Loss on early debt extinguishment
• Animal health net sales • Infant foods net sales • Non-GAAP tax adjustments
Twelve Months Ended
• Amortization expense related primarily to acquired intangible assets
• Change in financial assets
• Loss on investment securities
• Acquisition and integration-related charges and contingent
consideration adjustments
• Restructuring charges and other termination benefits
• Milestone income related to royalty rights
• Impairment charges
• Separation and reorganization expense
• (Gain) loss on divestitures
• Unusual litigation
• Foreign currency translation movement
• Animal health net sales
--------------------------------------------------------------------------------
• Infant foods net sales • Non-GAAP tax adjustments
The information in this Current Report on Form 8-K is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report on Form 8-K shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
--------------------------------------------------------------------------------
ITEM 9.01. Financial Statements and Exhibits
(d) Exhibits Exhibit Number Description 99.1 Press Release issued byPerrigo Company plc onFebruary 27, 2020 , furnished solely pursuant to Item 2.02 of Form 8-K. 104 Cover Page Interactive Data file (embedded within the Inline XBRL document).
--------------------------------------------------------------------------------
© Edgar Online, source
